Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019
Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019
复制标题
DOI：
10.1016/j.amjcard.2020.04.054
复制
发表时间：
2020-08-01
影响因子：
2.8
通讯作者：
Bangalore, Sripal
中科院分区：
文献类型：
--
作者：
Aggarwal, Gaurav;Henry, Brandon Michael;Bangalore, Sripal
2019冠状病毒病（COVID-19）已成为全球大流行病。它在大多数国家仍然不受控制，目前没有治疗方法。目前正在研究各种药物用于治疗。已知该疾病在患有基础心血管疾病的患者中具有更差的结果。氯喹/羟氯喹、阿奇霉素、瑞德西韦和洛匹那韦/利托那韦目前正在试验中进行研究，并显示出一定的前景。已报告使用这些药物会导致传导障碍、心力衰竭和死亡。在将这些药物用于COVID-19患者之前，了解这些药物的潜在心脏毒性作用非常重要，以便更好地分配医疗资源并改善临床结果。(C)2020爱思唯尔公司All rights reserved.
Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure, and mortality have been reported with the use of these drugs. It is important to have knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes. (C) 2020 Elsevier Inc. All rights reserved.